Intech Investment Management 13F: New $21M Stake in AZN

Intech Investment Management has taken a new position in AstraZeneca PLC (NYSE: AZN), according to its latest 13F filing with the SEC. The investment firm acquired 108,700 shares of the pharmaceutical company, valued at approximately $19.43 million. This move marks a new entry for the firm into AstraZeneca's stock.

What Changed in Intech Investment Management's AstraZeneca Position

Intech Investment Management's recent filing reflects a new buy of AstraZeneca shares. The firm now holds 108,700 shares, valued at $19.43 million, as of the latest reporting period. Previously, the firm did not hold any shares in AstraZeneca, marking this as a significant new position.

Other Institutional Activity in AstraZeneca

Several other institutional investors have also adjusted their holdings in AstraZeneca. Investor AB added 51,587,810 shares, bringing its total to about 51.59 million shares valued at $10.17 billion. Vanguard Capital Management LLC increased its stake by 45,040,142 shares, now holding approximately 45.04 million shares worth $8.81 billion. Capital International Investors boosted its holdings by 19,871,935 shares, ending with 34.39 million shares valued at $6.72 billion. FMR LLC grew its position by 7,752,869 shares for a total of 29.60 million shares worth $5.80 billion, and Capital World Investors added 27,350,501 shares, reaching a total of 28.26 million shares valued at $5.52 billion.

AstraZeneca PLC Stock Up 13.8%

Shares of AstraZeneca (NYSE: AZN) traded near $178.75. The company boasts a market cap of $277.22 billion and a P/E ratio of 27. Its stock has experienced a 52-week low of $137.22 and a high of $212.71. The 50-day moving average is $189.14, while the 200-day moving average stands at $182.05. AstraZeneca has a current ratio of 0.91 and a quick ratio of 0.70, with a debt-to-equity ratio of 71.82.

Recent Earnings

In its latest earnings report, AstraZeneca reported revenue of $60.44 billion, showing a growth rate of 12.5%. The company's net margin was 17.19%, with a return on equity of 23.48%. Earnings per share came in at $6.63. The next earnings release is scheduled for July 27, 2026.

Dividend

AstraZeneca pays an annual dividend rate of $3.16, yielding 1.77% with a payout ratio of 47.7%. Investors should note the ex-dividend date as it approaches.

Insider Buying and Selling at AstraZeneca PLC

Recent insider activity at AstraZeneca includes sales by Mani Sharma, SVP, Group Controller and Head of Global Finance Services, who sold 11,893 shares on May 20, 2026. Sharma also made minor purchases of 1 share each on May 6 and April 7, 2026. These transactions were not part of a pre-planned trading program.

Analysts Set New Price Targets

Analyst sentiment remains positive for AstraZeneca, with Cowen & Co. maintaining a "buy" rating and a target price of $95 on August 12, 2024. Goldman Sachs initiated coverage with a "buy" rating and a $97 target on May 30, 2024. The consensus among analysts is a "strong buy," with a mean target price of $224.49 based on 10 analyst opinions.

About AstraZeneca

AstraZeneca PLC is a major player in the healthcare sector, specializing in the development and commercialization of prescription medicines. Based in Cambridge, United Kingdom, the company operates in various therapeutic areas including oncology, cardiovascular, renal, and metabolism, as well as respiratory and immunology. Led by CEO Pascal Soriot, AstraZeneca employs approximately 96,100 people and serves markets across the globe, including the Americas, Europe, Asia, Africa, and Australasia.

Bottom Line

Intech Investment Management's new position in AstraZeneca reflects growing interest in the pharmaceutical giant. With strong institutional activity and positive analyst ratings, AstraZeneca remains a focal point for investors. However, it's important to remember that 13F filings are backward-looking and may not indicate current positions.